PRevention of End stage kidney disease by Darbepoetin Alfa In CKD patients with non-diabeTic kidney disease.

Not Applicable

• Conditions: Chronic Kidney Dosease patients without diabetes

• Registration Number: JPRN-UMIN000006616
• Lead Sponsor: PREDICT steering committee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-27
• Study Completion: 2016-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 440

Inclusion Criteria

Not provided

Exclusion Criteria

1) Diabetes (HbA1c 6.4% IFCC) 2) CKD patients treated with ESA other than epoetins. 3) CKD patients treated with epoetin 36000 IU or more. 4) Hypertension (180/10mmHg and higher) 5) Heart failure (NYHA III and IV) 6) malignancy, hematological disorder 7) malnuturition 8) Active and continuous gastrointestinal tract bleeding 9) ANCA associated glomerulonephritis, acute infection, active SLE 10) CKD patients who will be started dialysis or will receive tranplantation 11) Myocardial infarction within last 6 months 12) Stroke or plumonary embolism within last 12 months 13) Severe allergy 14) Pregnant woman or CKD patients who wish to be pregnant 15) Allergy against erythropoetin 16) CKD patients who is not appropriate to entry the clincal trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified